|
Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Kite, a Gilead company; Sanofi; Takeda |
Research Funding - Amgen; BioTheryX; Spectrum Pharmaceuticals |
|
|
Honoraria - Art tempi; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen-Cilag; Novartis |
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen-Cilag (Inst); Sanofi; Takeda (Inst) |
Speakers' Bureau - Art tempi; Bristol-Myers Squibb; Celgene; Chugai Pharma Europe; Janssen; Novartis |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma Europe (Inst); Janssen (Inst); Mundipharma (Inst); Novartis (Inst); Sanofi (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Novartis; Sanofi; Takeda |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - TeneoBio |
Research Funding - AMGEN (Inst); Genentech/Roche (Inst); Sanofi (Inst) |
|
|
Employment - Sanofi; SERVIER |
Stock and Other Ownership Interests - Sanofi |
|
|
Employment - Sanofi Pasteur |
Stock and Other Ownership Interests - Sanofi |
|
|
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Sanofi; Takeda |
Speakers' Bureau - Celgene; Janssen; Takeda |